Cstone Pharmaceuticals

Cstone Pharmaceuticals (Shanghai) Co., Ltd.

Cstone Pharmaceuticals (Suzhou) Co., Ltd.

Medshine Discovery Inc.

Nio (Anhui) Holding Co., Ltd.

Cisen Pharmaceutical Co., Ltd.

Cstone Pharmaceutical (Suzhou) Co., Ltd.

Novaonco Js Therapeutics Co., Ltd.

Cstone Pharmaceuticals Co., Ltd.

Yao Xiao

Changqing Wei

Shuhui Chen

Wenyuan Qian

Yonggang Liao

Qiang Guo

Zhengying Xi

Chen Zhang

Jian Li

Hao Wu

Bin Liu

Feng Wang

Yanbo Wang

Ye Yuan

Lili Fan

Jieying Zhang

Zhuanyao Gu

Guifen Zhang

Disclosed in the present invention is a series of dimethylsulfoximine derivatives, and specifically disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

Dimethylsulfoximine derivative

Disclosed are a diazaindole derivative as shown in formula I and the use thereof in the preparation of a drug for treating Chk1-related diseases. 

Diazaindole derivative and use thereof as CHK1 inhibitor

Disclosed in the present invention are a polymorph A of a compound represented by formula (I), and an application thereof in preparation of drugs for treating HDAC6-associated diseases. 

Polymorph of HDAC6-selective inhibitor and application thereof

The application provides a vehicle thermal management system, a vehicle thermal management method and a vehicle. The system includes: a flow path switching valve; a compressor, an in-cabin thermal management flow path; an out-cabin thermal management flow path; and at least one battery module thermal management flow path. A flow path switching valve of the system is used for switching the on/off and flow direction of an intake port of the compressor, an exhaust port of the compressor, the in-cabin thermal management flow path, the out-cabin thermal management flow path, and the battery module thermal management flow path.

Vehicle thermal management system, vehicle thermal management method and vehicle

Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. 

HDAC6 selective inhibitors, preparation method therefor, and application thereof

Growing community of inventors

Shanghai, China

Yao Xiao